Tepotinib with an EGFR-Tyrosine Kinase Inhibitor (TKI) in Patients with EGFR-mutant MET-amplified NSCLC: A Case Series

被引：0
|
作者：
Le, X. [1 ]
Eisert, A. [2 ]
Himpe, U. [3 ]
De Bondt, C. [4 ]
Mazieres, J. [5 ]
Petrini, I. [6 ]
Tho, L. M. [7 ]
Ahmad, A. [8 ]
Lam, W. -S. [9 ]
Chik, Y. K. J. [10 ]
Lee, W. C. K. [11 ]
Yang, T. -Y. [12 ]
Joshi, K. [13 ,14 ]
Berghoff, K. [13 ]
Vlassak, S. [13 ]
Karachaliou, N. [13 ]
v. d. Wekken, A. [15 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Univ Hosp Cologne, Ctr Integrated Oncol Aachen Bonn Cologne Duesseld, Cologne, Germany
[3] AZ Delta Roeselare Menen Torhout, Roeselare, Belgium
[4] Antwerp Univ Hosp, Edegem, Belgium
[5] Univ Paul Sabatier, CHU Toulouse, Toulouse, France
[6] Univ Hosp Pisa, Pisa, Italy
[7] Pantai Hosp Kuala Lumpur, Kuala Lumpur, Malaysia
[8] Beacon Hosp, Petaling Jaya, Selangor, Malaysia
[9] Western Haematol & Oncol Clin, Perth, Australia
[10] Queen Elizabeth Hosp, Hong Kong, Peoples R China
[11] Prince Wales Hosp, Hong Kong, Peoples R China
[12] Taichung Vet Gen Hosp, Taichung, Taiwan
[13] Merck Healthcare KGaA, Darmstadt, Germany
[14] ICON Plc, Dublin, Ireland
[15] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
Tepotinib; EGFR; MET;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.02-16
引用
收藏
页码：S483 / S484
页数：2
相关论文
共 50 条
  • [41] Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
    Wenxian Wang
    Hong Wang
    Peihua Lu
    Zongyang Yu
    Chunwei Xu
    Wu Zhuang
    Zhengbo Song
    [J]. Journal of Translational Medicine, 17
  • [42] Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
    Wang, Wenxian
    Wang, Hong
    Lu, Peihua
    Yu, Zongyang
    Xu, Chunwei
    Zhuang, Wu
    Song, Zhengbo
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2019, 17 (1)
  • [43] A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor (TKI) naive patients with advanced NSCLC.
    Lisberg, Aaron Elliott
    Cummings, Amy Lauren
    Goldman, Jonathan Wade
    Bornazyan, Krikor
    Reese, Nicholas Dean
    Wang, Tina
    Coluzzi, Paul
    Ledezma, Blanca A.
    Mendenhall, Melody A.
    Jones, Benjamin
    Madrigal, John
    Carroll, James M.
    Gukasyan, Jaklin
    Williams, Tawny
    Sauer, Lauren
    Wells, Courtney L.
    Hardy, Ariana R.
    Linares, Paulina J.
    Adame, Carlos R.
    Garon, Edward B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [44] EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC
    Stock-Martineau, Sophie
    Shepherd, Frances A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (11) : 1793 - 1797
  • [45] Associations of C-MET Gene Copy with EGFR Mutation and Gene Copy in EGFR-Tyrosine Kinase Inhibitor (TKI) Untreated Non-Small Cell Lung Cancer (NSCLC)
    Bae, J. M.
    Jeon, Y. K.
    Kim, Y. T.
    Seo, J. W.
    Kim, Y. A.
    Chung, D. H.
    [J]. LABORATORY INVESTIGATION, 2010, 90 : 397A - 397A
  • [46] Dependence of EGFR-mutant NSCLC on MET as demonstrated by vebreltinib, a novel and selective brain-penetrating MET kinase inhibitor
    Zhang, Xiaoling
    Liu, Elaine
    Song, Yan
    Yu, Peony
    Redkar, Sanjeev
    Yu, Guo-Liang
    [J]. CANCER RESEARCH, 2024, 84 (06)
  • [47] Tepotinib plus gefitinib vs chemotherapy in MET-amplified EGFR-mutant non-small cell lung cancer (NSCLC): Predefined subgroup analysis of a Phase Ib/II study
    Yang, James Chih-Hsin
    Zhou, Jianying
    Kim, Dong-Wan
    Ahmad, Azura Rozila
    Soo, Ross Andrew
    Bruns, Rolf
    Straub, Josef
    Johne, Andreas
    Scheele, Juergen
    Park, Keunchil
    Wu, Yi-Long
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [48] Associations of C-MET Gene Copy with EGFR Mutation and Gene Copy in EGFR-Tyrosine Kinase Inhibitor (TKI) Untreated Non-Small Cell Lung Cancer (NSCLC)
    Bae, J. M.
    Jeon, Y. K.
    Kim, Y. T.
    Seo, J. W.
    Kim, Y. A.
    Chung, D. H.
    [J]. MODERN PATHOLOGY, 2010, 23 : 397A - 397A
  • [49] Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation
    Yamaoka, Toshimitsu
    Ohmori, Tohru
    Ohba, Motoi
    Arata, Satoru
    Kishino, Yasunari
    Murata, Yasunori
    Kusumoto, Sojiro
    Ishida, Hiroo
    Shirai, Takao
    Hirose, Takashi
    Ohnishi, Tsukasa
    Sasaki, Yasutsuna
    [J]. MOLECULAR CANCER THERAPEUTICS, 2016, 15 (12) : 3040 - 3054
  • [50] A case of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with MET amplification and epithelial-to-mesenchymal transition
    Miyoshi, Seigo
    Kato, Takahide
    Katayama, Hitoshi
    Ito, Ryoji
    Mizuno, Yosuke
    Okura, Takafumi
    Higaki, Jitsuo
    [J]. ONCOTARGETS AND THERAPY, 2015, 8 : 783 - 787
12345